- Home
- PLRX vs ARCT Comparison
PLRX vs ARCT Comparison
Compare PLRX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | ARCT |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 194.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLRX | ARCT |
|---|---|---|
| Price | $1.22 | $6.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $3.79 | ★ $38.67 |
| AVG Volume (30 Days) | ★ 1.8M | 706.5K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $97,601,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $5.85 |
| 52 Week High | $14.26 | $24.17 |
Technical Indicators
Market Signals| Indicator | PLRX | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 34.10 |
| Support Level | $1.20 | $6.34 |
| Resistance Level | $1.27 | $6.75 |
| Average True Range (ATR) | 0.07 | 0.39 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 20.00 | 2.30 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.